

Article title	How to Integrate Personalized Medicine into Prevention? Recommendations from the Personalized Prevention of Chronic Diseases (PRECeDI) Consortium
Article title second language	
Article title third language	
Subtitle	
Short title	Personalized Medicine and Prevention
Section title	Research Article

Relation(s)	Example:	Initials S.-J.	Given name Seo-Jin	Surname/Collaboration Park	Affiliation(s) a,b
2458437		S.	Stefania	Boccia	a,b
2458438		R.	Roberta	Pastorino	b
2458430		W.	Walter	Ricciardi	a,b
2458431		R.	Róza	Ádány	c
2458439		F.	Floris	Barnhoorn	d
2458440		P.	Paolo	Boffetta	e
2458432		M.C.	Martina	Cornel	f
2458433		C.	Corrado	De Vito	g
2458441		M.	Muir	Gray	h
2458442		A.	Anant	Jani	h
2458443		M.	Michael	Lang	i
2458444		J.	Jim	Roldan	j
2458445		A.	Annalisa	Rosso	g
2458446		J.M.	José Manuel	Sánchez	j
2458447		C.	Cornelia	Van Dujin	k
2458434		C.G.	Carla	Van El	f
2458435		P.	Paolo	Villari	g
2458436		M.H.	Ma'n H.	Zawati	i

Affiliation(s)	City	State	Country
a Section of Hygiene, Institute of Public Health, Università Cattolica del Sacro Cuore	Rome		Italy
b Department of Woman and Child Health and Public Health – Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS	Rome		Italy
c Department of Preventive Medicine, Debrecen University	Debrecen		Hungary
d European Public Health Association	Utrecht		The Netherlands
e Institute for Translational Epidemiology, Icahn School of Medicine	New York	NY	USA

f	Department of Clinical Genetics and Amsterdam Public Health research institute, Vrije Universiteit Amsterdam, Amsterdam University Medical Centers, location VUmc	Amsterdam	The Netherlands
g	Department of Public Health and Infectious Diseases, Sapienza University of Rome	Rome	Italy
h	Better Value Health Care	Oxford	UK
i	Centre of Genomics and Policy, McGill University	Quebec	QC Canada
j	Linkcare Health Services S.L.	Barcelona	Spain
k	Department of Epidemiology, Erasmus University Medical Center	Rotterdam	The Netherlands

Additional information	
------------------------	--

Corresponding author	Stefania Boccia, PhD

Citation line	Journal			
	Public Health Genomics			
Translation				
10.1159/000504652	Article-Nr	504652	CCCode	
ISSN	1662-4246			
ISBN				

Received	Received: October 31, 2019
Accepted	Accepted: November 2, 2019
Revised	
Published online	Published online: ■■■
Copyright statement	© 2019 S. Karger AG, Basel
Copyright description	

Keywords	Keywords
	Recommendations Personalized medicine Prevention Chronic diseases

Keywords Second Language	

Keywords Third Language	

Abbreviations	
---------------	--

Abstract	Abstract
----------	----------

Medical practitioners are increasingly adopting a personalized medicine (PM) approach involving individually tailored patient care. The Personalized Prevention of Chronic Diseases (PRECeDI) consortium project, funded within the Marie Skłodowska Curie Action (MSCA) Research and Innovation Staff Exchange (RISE) scheme, had fostered collaboration on PM research and training with special emphasis on the prevention of chronic diseases. From 2014 to 2018, the PRECeDI consortium trained 50 staff members on personalized prevention of chronic diseases through training and research. The acquisition of skills from researchers came from dedicated secondments from academic and nonacademic institutions aimed at training on several research topics related to personalized prevention of cancer and cardiovascular and neurodegenerative diseases. In detail, 5 research domains were addressed: (1) identification and validation of biomarkers for the primary prevention of cardiovascular diseases, secondary prevention of Alzheimer disease, and tertiary prevention of head and neck cancer; (2) economic evaluation of genomic applications; (3) ethical-legal and policy issues surrounding PM; (4) sociotechnical analysis of the pros and cons of informing healthy individuals on their genome; and (5) identification of organizational models for the provision of predictive genetic testing. Based on the results of the research carried out by the PRECeDI consortium, in November 2018, a set of recommendations for policy makers, scientists, and industry has been issued, with the main goal to foster the integration of PM approaches in the field of chronic disease prevention.

Abstract Second Language	
--------------------------	--

Abstract Third Language	
-------------------------	--

Key Messages	

Body

The Promise of Personalized Prevention

Personalization of healthcare is a driver of innovation in research, healthcare systems, and industry. Policy makers, healthcare professionals, citizens, and private companies need proper advice to realize its potential. The Personalized Prevention of Chronic Diseases (PRECeDI) consortium is a Marie Skłodowska Curie Action (MSCA) project funded within the Research and Innovation Staff Exchange (RISE) scheme that aimed at providing high-quality, multidisciplinary knowledge through training and research in personalized medicine (PM), with specific reference to personalized prevention of chronic diseases. PM approaches are already being implemented especially in the fields of disease diagnosis and treatment with the use of biomarkers; however, development and implementation of such approaches for chronic disease prevention needs further investigation and concerted efforts for proper implementation in healthcare systems.

We must be explicit about the new potential benefits that disease prevention can bring in the context of PM. Technological advances, jointly with current

demographic trends and the expectations of citizens, have the potential to widen the gap between available resources and the requirements for healthcare. As highlighted by the European Steering Group on Sustainable Healthcare, the implementation of sustainable healthcare requires a shift from treatment of established disease to disease prevention and early diagnosis, and it relies on the need to engage citizens in taking greater responsibility for their health in order to establish a more participatory healthcare model [1]. Despite the tremendous increase in life expectancy in Europe in the last 50 years, the latest Eurostat reports that the average number of years of life lived with some disability in Europe is 19.4 for females and 17.7 for males [2]. Although it is acknowledged that prevention in healthcare can improve the quality of life at a very reasonable price by reducing the years of life spent with disability, only 2.8% of health expenditure is for prevention activities [3]. Personalized prevention approaches bring the promise of being even more effective and cost-effective by using the latest advancements in life sciences and (digital) technologies to stratify healthy individuals based on individual and environmental factors, in order to target precise primary, secondary, and tertiary prevention interventions. Such an approach is supported by a highly cited 2008 editorial in *New England Journal of Medicine*, which reported that "... if preventive care could be provided only to those who are going to get the illness, it would be more cost-effective" [4].

PRECeDI

Laying the Foundation for Making Personalized Prevention a Reality

The PRECeDI consortium consists of 8 beneficiaries and 3 partners, of which 7 are academic institutions and 4 nonacademic, including 2 small and medium-sized enterprises (SMEs), and it received funding from the Horizon 2020 (H2020) European Union's Eight Framework Programme for Research [5–7]. During 4 years (2014–2018), 28 early-stage researchers and 22 experienced researchers were seconded for an average of 3 months from academic to nonacademic institutions and vice versa, for training in research projects related to the personalized prevention of chronic diseases, including cancer, cardiovascular diseases, and Alzheimer disease.

Different projects were carried out, from basic research to economic evaluations, from health service organization issues to physician education, including ethical, social, and policy issues in PM, supported by a team of leading EU scientists. The consortium is embedded in existing cooperative structures, such as ICPeMed [8] and TO-REACH [9], the IMPACT-HTA project funded from the H2020 program [10], and the Joint Action iPAAC funded by the Third EU Health Programme [11].

How PRECeDI Contributes to the Integration of PM in the Prevention of Chronic Diseases

Based on the results of the research carried out by the PRECeDI consortium, a set of recommendations for policy makers, scientists, and industry has been drawn up, with the main goal to foster the integration of PM approaches in the field of chronic disease prevention. As a reflection of the work carried out during the project, most of the recommendations fall in the “translational phase of research in genomics,” as defined by Khoury et al. [12], in “T1 (seeks to move a basic genome-

based discovery into a candidate health application)” and “T3 (attempts to move evidence-based guidelines into health practice, through delivery, dissemination, and diffusion research).”

In particular, these recommendations fall within the 5 research domains of PRECeDI [5]: “Identification of biomarkers for the prevention of chronic diseases; economic evaluation of predictive genomic applications; ethico-legal and policy issues surrounding personalized medicine; sociotechnical analysis of the pros and cons of informing healthy individuals on their genome; identification of organizational models for the provision of predictive genetic testing”.

In addition, when formulating the recommendations, the PRECeDI consortium considered 2 main additional documents: the Strategic Research and Innovation Agenda (SRIA) published in 2016 by the PerMed consortium [13] and the report published in 2017 from the PHG Foundation (Hall and Luheshi [14]; Ricciardi and Boccia [15]). PerMed SRIA reported 5 challenges for the further implementation of PM in Europe, namely: “Developing Awareness and Empowerment; Integrating Big Data and ICT Solutions; Translating Basic to Clinical Research and Beyond; Bringing Innovation to the Market; Shaping Sustainable Healthcare” [13]. The 2017 PHG Foundation Report, as recalled by Ricciardi and Boccia [15], incorporated a public health perspective and reported 6 prerequisites to implement the future of personalized healthcare: “Achieving better genetic literacy for professionals and for the public; engaging citizens in the discourse; improved governance, consent and trust in healthcare; feeding and harnessing the data – knowledge cycle for better health; adopting and adapting the Health Technology Assessment framework for the

evaluation of the new technologies; and retaining humanity and community in health and care.”

Taking into account that personalized prevention can only be successfully implemented when handled as a truly cross-sectoral topic, our recommendations integrate the perspective of experts across the entire healthcare value chain that are represented in the PRECeDI consortium.

As a matter of fact, the recommendations are also the result of the discussions of the one-day PRECeDI workshop “Policy Development in Personalized Medicine” held in Amsterdam on March 15th, 2018 [16], that convened experts and representatives of relevant stakeholders in the field of PM. The experts participating fully endorsed the document.

These recommendations are formulated as a direct output of the research results and the scientific publications produced by the PRECeDI consortium. The implementation of the recommendations will benefit citizens, patients, healthcare professionals, healthcare authorities, and industry and ultimately seek to contribute to better health for Europe’s citizens.

In order to be fully shared and endorsed by relevant authorities and decision makers, this document has been published and open to a public consultation via the PRECeDI website [6].

Below, we report the recommendations that are based on the results of the projects carried out within the 5 research domains of PRECeDI that integrate the 2 sets of aforementioned recommendations (PerMed consortium [13]; Ricciardi and Boccia [15]) (Table 1).

Recommendation 1

Recommendation 1 is based on the “identification of biomarkers for the prevention of chronic diseases” research domain.

Biomarkers have the potential to stratify populations because they can help to indicate an individual's risk or resistance to disease as well as the potential response the individual may have to different treatments. There is also an expectation that this may lead to better targeting of preventive interventions by defining the disease and targeting the treatment based on a person's molecular pathology.

R1. Personalized interventions for the prevention of chronic diseases require robust evidence of efficacy and/or effectiveness of the new technology when implemented in healthcare.

In particular, large trials evaluating the efficacy of disease risk communication based on broad-range newly discovered biomarkers (vs. risk communication based on the solely traditional risk factors) on behavioral change among healthy subjects at increased risk are required for targeted evidence-based primary preventive interventions. For biomarkers that allow discriminating high-risk subjects, large trials evaluating the efficacy of medical interventions are required among such high-risk subjects for targeted evidence-based primary and secondary preventive interventions.

Where intervention studies cannot be performed, however, the use of large datasets, Big Data from collaborative research projects, should be considered for the evidence of effectiveness. In order to ensure timely results for the use of such predictive biomarkers, the collection of such evidence by action research should be foreseen in the course of implementation and accompanied by collection of genetic

data to allow for state-of-the Mendelian Randomization studies to mimic conventional trials.

In these situations, a clear commitment to hypothesis to be tested in advance is needed as is the case with (the registration of) classical trials.

For tertiary prevention, the adoption of accurate biomarkers for precise monitoring and early prediction of disease progression should be encouraged.

This recommendation is based on the results of the biomarkers identified (and validated) for the prevention of diabetes [17, 18], Alzheimer disease [19], and head and neck cancer [20–22].

Recommendation 2

Recommendation 2 is based on the “economic evaluation of predictive genomic applications” research domain.

The growing availability of genomic technologies is contributing to the shift of the medical approach towards PM, where medical decisions are based on an individual’s characteristics, including the genomic profile. This has made the assessment of the performance of genomic tests crucial for clinical and public health practice. In fact, in order to maximize population health benefits, it is essential to distinguish genomic tests with proven efficacy and/or effectiveness and cost-effectiveness and support their implementation.

R2. A comprehensive evaluation of the value (outcomes/cost) of genetic and genomic applications should include evidence on the efficacy and/or effectiveness of the new technology (i.e., analytic validity, clinical validity, clinical utility), social aspects (ethical, legal, and social implications, and personal utility), and context-

related dimensions (e.g., economic evaluation, delivery models, organizational aspects, and consumer viewpoint) to better support the decision-making process.

Genetic or genomic applications with evidence of efficacy, effectiveness, and cost-effectiveness should be implemented in clinical and public health practice (i.e., programs that include tools for identifying affected women at higher risk for inherited breast and ovarian cancers or familial history-based screening for BRCA1/2; universal or <70 years of age-targeted colorectal cancer-based Lynch syndrome screening; cascade screening of familial hypercholesterolemia). The genomic or genetic testing programs and their implementation should be developed and pursued based on the characteristics of target populations and healthcare systems to ensure an appropriate translation of evidence into the “real world.”

The implementation of a genetic or genomic application should be continuously assessed, measuring the population health impact and relative value of new technologies.

Adherence to the programs should be monitored, and the education and training of clinical and public health professionals should be promoted with the aim of reducing inappropriate use in healthcare.

This recommendation is based on the results of a systematic review for the identification of the domains for an appropriate evaluation of genetic/genomic technologies [23, 24]; systematic reviews on the cost-effectiveness of genomic applications [25–27]; a perspective on the main characteristics to consider for an appropriate implementation [28, 29]; 2 surveys on (1) patient experience throughout the delivery pathways and (2) knowledge and attitudes of European public health

professionals on the delivery of genetic services and a systematic review on patient management [\[30–32\]](#).

Recommendation 3

Recommendation 3 is based on the “ethico-legal and policy issues surrounding personalized medicine” research domain.

There is an increasing need for a coordinated effort to foster the development and further harmonization of dedicated policies to integrate genomics policies into existing health systems in a responsible manner. Introducing a common ethically and legally validated policy framework could represent one of the drivers needed to manage a future with increasingly personalized healthcare and a shift in the use of genomic approaches from disease treatment to prevention.

R3. The era of genomics requires that we clarify and validate the obligations and responsibilities of the research community, research participants, and the general public. This can be achieved through collaboration and dissemination of high-quality ethical, policy, and legal analysis. Legal interoperability is necessary to ensure complementarity of goals between researchers in different jurisdictions.

In order to be at the forefront of the currently shifting research landscape, we need to draw on multiple levels of expertise (e.g., law, ethics, medicine, bioinformatics, IT) in an array of multidisciplinary, jurisdictional, and institutional settings.

Finally, a metric assessing the impact of policy development or lack thereof is a fundamental tool to fine-tune guidance to multiple stakeholders.

This recommendation is based on the results of a survey performed among the Europeans Chief Medical Officers on the genomics policies in healthcare [33].

Recommendation 4

Recommendation 4 is based on the “sociotechnical analysis of the pros and cons of informing healthy individuals on their genome” research domain.

Genetic testing of family members of patients affected with hereditary cancers or cardiovascular diseases allows for personalized prevention and it is paramount to find and inform these family members in a timely manner. Several countries are building cascade screening programs and they are discussing how family members can be traced and informed in an ethically responsible and efficient manner. In conditions where genetic testing offers a substantial and quantifiable risk estimate and prevention is available, preventive services should be prioritized. More government involvement is needed as a formally organized screening program could standardize support and information and lead to more equitable healthcare.

R4. A dedicated effort is necessary to stimulate further ethically responsible implementation of evidence-based interventions in healthcare, such as testing of family members in cases of hereditary cancers or cardiovascular diseases. Where guidelines for such genetic testing exist, collaboration between genetic and nongenetic healthcare professionals needs to be facilitated to improve implementation, education opportunities must be provided, and roles and responsibilities towards informing family members must be reconsidered so we can achieve a truly multidisciplinary approach that can realize the potential of PM.

This recommendation is based on the results of a sociotechnical analysis for familial hypercholesterolemia [34].

Recommendation 5

Recommendation 5 is based on the “identification of organizational models for the provision of predictive genetic testing” research domain.

The identification and evaluation of existing genetic service delivery models are important steps towards the enhancement and standardization of genetic service provision. Integration of genetics in all medical specialties, collaboration among different healthcare professionals, and redistribution of professional roles are fundamental elements for the organization of these models. Furthermore, their implementation must hinge on professional education, adequate funding, and public awareness in the field of genomic medicine.

R5. The integration of genetics in other medical specialties should be promoted through new delivery models involving different healthcare professionals (medical specialists, nurses, technicians, etc.) and new professional roles (i.e., genetic counsellors, genetic associates, genetic nurses), in order to guarantee the use and sustainability of existing and new genomic applications in practice.

Roles and responsibilities (e.g., risk assessment, genetic counseling, genetic testing) should be redistributed among different health professionals to enhance work performance and the standard of care.

It is advisable to define the appropriate model for genetic service provision in a specific setting according to the type of healthcare system and the genetic test provided.

Professional education/training in genomics medicine, laboratory quality standards, and public awareness are essential factors for the successful implementation of genomic applications in practice.

This recommendation is based on the results of a systematic review focusing on existing genetic service delivery models [35, 36]; a perspective on the main characteristics to consider for an appropriate implementation [28, 37, 38]; and 3 surveys on (1) patient experience throughout the delivery pathways, (2) genetic services' delivery models in European countries, and (3) knowledge and attitudes of European public health professionals on the delivery of genetic services [31, 39].

Acknowledgments

The PRECeDI consortium would like to thank Natasha Azzopardi Muscat (European Public Health Association, Department of Health Services Management, University of Malta), Martine de Bruijne (Amsterdam Public Health Research Institute), Paolo Gazzaniga (Assobiomedica), Maurizio Genuardi (Institute of Genomic Medicine, Università Cattolica del Sacro Cuore), Denis Horgan (European Alliance for Personalised Medicine), Tessel Rigter (Netherlands Institute for Public Health and the Environment), Dick Willems (Amsterdam Public Health), Ron Zimmern (PHG Foundation), Elvira D'Andrea, Erica Pitini, Brigid Unim (Department of Public Health and Infectious Diseases, Sapienza University of Rome), Laura Motta (Università Cattolica del Sacro Cuore, Ricerca Roma – Grant Office), Sabrina Montante (Università Cattolica del Sacro Cuore, Brussels Office), and Marco Mariani

(Sezione di Igiene, Università Cattolica del Sacro Cuore) for the contribution to the PRECeDI recommendations.

Statement of Ethics

The ethical approval was not required, as not applicable to our research. According to the study design, no medical treatments nor procedures involving humans nor animals were performed.

Disclosure Statement

The authors have no conflict of interest to declare.

Funding Sources

The PRECeDI project has received funding from the European Union's Horizon 2020 research and innovation programme MSCA-RISE-2014: Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) under the grant agreement No. 645740.

Author Contributions

S.B. conceived and coordinated the study. R.P. managed the project. S.B., R.P., C.V.D., R.A., and P.B. were involved in Research Domain (RD) 1. P.V., C.D., and A.R. were involved in RD2 and RD5. S.B., W.R., R.P., F.B., M.H.Z., and M.L. were involved in RD3. M.C. and C.V.E. were involved in RD4. M.G., A.J., J.R., and

J.M.S. were involved in R5. All authors discussed, drafted, and critically reviewed the manuscript and approved the final version.

References

- 1 Harney M. Acting Together: A Roadmap for Sustainable Healthcare. 2016. Available from: <https://www.sustainable-healthcare.com/content-ass>
- 2 European Commission. Eurostat. 2018. Available from: <https://ec.europa.eu/eurostat/web/health>
- 3 Gmeinder M, Morgan D, Mueller M. How much do OECD countries spend on prevention? *OECD Health Work Pap*. 2017, Epub ahead of print.
- 4 Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. *N Engl J Med*. 2008 Feb;358(7):661–3.
- 5 Boccia S, Pastorino R. Editorial. *Epidemiol Biostat Public Health*. 2015;12(2), Epub ahead of print.
- 6 PRECeDI consortium. PRECeDI. 2019. Available from: <http://www.precedi.eu/site/index.php>
- 7 European Commission. Personalised medicine for disease prevention 2019. Available from: https://ec.europa.eu/research/infocentre/article_en.cfm?artid=49872
- 8 ICPeMed Consortium. ICPeMed. 2019. Available from: www.ICPeMed.eu
- 9 TO-REACH consortium. TO-REACH. 2019. Available from: <https://to-reach.eu/>
- 10 IMPACT-HTA consortium. Improved methods and actionable tools for enhancing HTA. 2019. Available from: <https://www.impact-hta.eu/>

- 11 iPAAC consortium. Innovative Partnership for Action Against Cancer (iPAAC) Joint Action. 2019 [. Available from: <https://www.ipaac.eu/>
- 12 Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? [Genet Med](#). 2007 Oct;9(10):665–74.
- 13 PerMed Consortium. Shaping Europe’s Vision for Personalised Medicine: Strategic Research and Innovation Agenda (SRIA) [Internet]. 2019. Available from: https://www.permed2020.eu/_media/PerMed_SRIA.pdf
- 14 Hall A, Luheshi L. Personalised healthcare: bringing the future into focus. 2017 Available from: <https://www.phgfoundation.org/documents/REPORT%20-%20Personalised%20healthcare%20bringing%20the%20future%20into%20focus.pdf>
- 15 Ricciardi W, Boccia S. New challenges of public health: bringing the future of personalised healthcare into focus. [Eur J Public Health](#). 2017 Oct;27(suppl_4):36–9.
- 16 Boccia S. PRECeDI Open Seminar. 2018 . Available from: <http://www.precedi.eu/site/index.php/courses/seminars-and-conferences>
- 17 Liu J, van Klinken JB, Semiz S, van Dijk KW, Verhoeven A, Hankemeier T, et al. A Mendelian Randomization Study of Metabolite Profiles, Fasting Glucose, and Type 2 Diabetes. [Diabetes](#). 2017 Nov;66(11):2915–26.
- 18 Fiatal S, Ádány R. Application of Single-Nucleotide Polymorphism-Related Risk Estimates in Identification of Increased Genetic Susceptibility to

- Cardiovascular Diseases: A Literature Review. [Front Public Health](#). 2018 Jan;5:358.
- 19 van der Lee SJ, Teunissen CE, Pool R, Shipley MJ, Teumer A, Chouraki V, et al. Circulating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies. [Alzheimers Dement](#). 2018 Jun;14(6):707–22.
 - 20 Giraldi L, Leoncini E, Pastorino R, Wünsch-Filho V, de Carvalho M, Lopez R, et al. Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: a pooled analysis within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. [Ann Oncol](#). 2017 Nov;28(11):2843–51.
 - 21 Leoncini E, Vukovic V, Cadoni G, Giraldi L, Pastorino R, Arzani D, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. [Eur J Epidemiol](#). 2018 Dec;33(12):1205–18.
 - 22 Boccia. MicroRNA (miRNA) profiles, lifestyle factors, and their interaction in Head and Neck Cancer (HNC) risk and prognosis [Internet]. 2013. Available from: <https://www.inhance.utah.edu/pubproj.php>
 - 23 Pitini E, De Vito C, Marzuillo C, D'Andrea E, Rosso A, Federici A, et al. How is genetic testing evaluated? A systematic review of the literature. [Eur J Hum Genet](#). 2018 May;26(5):605–15.
 - 24 Tognetto A, Michelazzo MB, Calabró GE, Unim B, Di Marco M, Ricciardi W, et al. A Systematic Review on the Existing Screening Pathways for Lynch Syndrome Identification. [Front Public Health](#). 2017 Sep;5:243.

- 25 D'Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, et al. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. [Genet Med](#). 2016 Dec;18(12):1171–80.
- 26 Di Marco M, D'Andrea E, Panic N, Baccolini V, Migliara G, Marzuillo C, et al. Which Lynch syndrome screening programs could be implemented in the “real world”? A systematic review of economic evaluations. [Genet Med](#). 2018 Oct;20(10):1131–44.
- 27 Rosso A, Pitini E, D'Andrea E, Massimi A, De Vito C, Marzuillo C, et al. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review. [Ann Ig](#). 2017 Sep-Oct;29(5):464–80.
- 28 Di Marco M, D'Andrea E, Villari P. Universal screening of Lynch syndrome is ready for implementation. [Genet Med](#). 2019 Jan;21(1):254–5.
- 29 Pastorino R, Tognetto A, Boccia S. Screening Programs for Lynch Syndrome in Italy: State of the Art and Future Challenges. [Epidemiol Biostat Public Health](#). 2017;14(2), Epub ahead of print.
- 30 D'Andrea E, Lagerberg T, De Vito C, Pitini E, Marzuillo C, Massimi A, et al. Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia. [Eur J Hum Genet](#). 2018 Apr;26(4):518–26.
- 31 Rosso A, D'Andrea E, Di Marco M, Pitini E, Unim B, De Vito C, et al. European survey on knowledge and attitudes of public health professionals on public health genomics: Pilot Study. [Epidemiol Biostat Public Health](#). 2017;14(3), Epub ahead of print.

- 32 Migliara G, Baccolini V, Rosso A, D'Andrea E, Massimi A, Villari P, et al. Familial Hypercholesterolemia: A Systematic Review of Guidelines on Genetic Testing and Patient Management. [Front Public Health](#). 2017 Sep;5:252.
- 33 Mazzucco W, Pastorino R, Lagerberg T, Colotto M, d'Andrea E, Marotta C, et al. Current state of genomic policies in healthcare among EU member states: results of a survey of chief medical officers. [Eur J Public Health](#). 2017 Oct;27(5):931–7.
- 34 van El CG, Baccolini V, Piko P, Cornel MC. Stakeholder Views on Active Cascade Screening for Familial Hypercholesterolemia. [Healthcare \(Basel\)](#). 2018 Aug;6(3):108.
- 35 Unim B, Lagerberg T, Pitini E, De Vito C, Vacchio MR, Adamo G, et al. Identification of Delivery Models for the Provision of Predictive Genetic Testing in Europe: Protocol for a Multicentre Qualitative Study and a Systematic Review of the Literature. [Front Public Health](#). 2017 Aug;5:223.
- 36 Unim B, Lagerberg T, Adamo G, Pitini E, D'Andrea E, Vacchio MR, et al. Delivery models for predictive genetic testing: preliminary results of a systematic review. [Eur J Public Health](#). 2016 Nov;26(suppl_1), Epub ahead of print.
- 37 Cornel MC, van El CG. Barriers and Facilitating Factors for Implementation of Genetic Services: A Public Health Perspective. [Front Public Health](#). 2017 Aug;5:195.
- 38 Bíró K, Dombrádi V, Jani A, Boruzs K, Gray M. Creating a common language: defining individualized, personalized and precision prevention in public health. [J Public Health \(Oxf\)](#). 2018 Dec;40(4):e552–9.

- 39 Rosso A, D'Andrea E, Di Marco M, Pitini E, Unim B, Baccolini V, et al. Interim results of EUPHA network members's survey on Public Health Genomics. [Eur J Public Health](#). 2017 Nov;27(suppl_3), Epub ahead of print.

Appendix after References (Editorial Comments)

Legend(s)

Table(s)

Footnote(s)

Table 1. The PRECeDI Recommendations

PRECeDI Domains	PRECeDI Recommendations
<i>Domain 1:</i> Identification of biomarkers for the prevention of chronic disease	<i>R1.</i> Personalized interventions for the prevention of chronic diseases require robust evidence of efficacy and/or effectiveness of the new technology when implemented in healthcare.
<i>Domain 2:</i> Economic evaluation of predictive genomic applications	<i>R2.</i> In addition to what is reported in R1, a comprehensive evaluation of the value (outcomes/cost) of the new technology should also include evidence on the social aspects and context-related dimensions to better support the clinical decision-making process. Genetic or genomic applications with evidence of efficacy, effectiveness, and cost-effectiveness should be implemented in clinical and public health practice.
<i>Domain 3:</i> Ethico-legal and policy issues surrounding personalized medicine	<i>R3.</i> The era of genomics requires that we clarify and validate the obligations and responsibilities of the research community, research participants, and the general public including patients through collaboration and dissemination of high-quality ethical, policy, and legal analysis.
<i>Domain 4:</i> Sociotechnical analysis of the pros and cons of informing healthy individuals on their genome	<i>R4.</i> A dedicated effort is necessary to stimulate further implementation of evidence-based interventions in healthcare, such as testing of family members in cases of hereditary cancers or cardiovascular diseases.
<i>Domain 5:</i> Identification of organizational models for the provision of predictive genomic applications	<i>R5.</i> The integration of genomic sciences in other medical specialties should be promoted through new delivery models involving different healthcare professionals and new professional roles, in order to guarantee the use and sustainability of existing and new genomic applications in practice.